Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The European drug market could soon be poised to receive three new entries, as the European Committee for Healthcare and…
24 Apr 2026
OZMOSI and Planview partner to enhance pharmaceutical data integration
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform. The initiative aims to link external…
24 Apr 2026
Regeneron cuts White House pricing deal, offers new gene therapy for free
It’s been a busy few days for Regeneron Pharmaceuticals, which has inked a drug pricing agreement with the White House, while pledging to offer its newly approved rare hearing loss…
24 Apr 2026
Cumberland to sell drug portfolio to Apotex for $100m
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash. Under the agreement, Apotex will acquire Cumberland's branded medicines for…
23 Apr 2026
500,000 patients’ data for sale online after UK Biobank breach
Last week, data from 500,000 participants of UK Biobank’s database were made available for sale online following a breach, the UK Government’s technology minister has confirmed. In an oral statement…
23 Apr 2026
Sanofi receives FDA approval for Tzield in paediatric diabetes
Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield (teplizumab-mzwv), allowing its use to delay stage 3 type 1…
23 Apr 2026
AbbVie opts for North Carolina to house $1.4bn manufacturing site
AbbVie has tapped North Carolina as the location for a new $1.4bn manufacturing site as part of its $100bn US manufacturing pledge – adding another giant to the growing list…